Illinois Nurse Newlove Stripped of DEA Access Over Expired Credentials
Published Date: 7/8/2025
Notice
Summary
Tanya Newlove, a nurse practitioner from Illinois, lost her DEA registration because her state licenses expired and she didn’t ask for a hearing to defend herself. This means she can no longer handle controlled substances legally, effective immediately. If you’re a healthcare provider, this reminds you to keep your licenses current or risk losing important permissions.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
DEA Registration Revoked for Nurse Practitioner
The Drug Enforcement Administration revoked Tanya Newlove's DEA Certificate of Registration No. MD3642077, effective August 6, 2025. This means she can no longer legally handle or dispense controlled substances after that date because her Illinois licenses expired on June 30, 2024.
Pending Renewal/Additional Applications Denied
The Order denies any pending applications by Tanya Newlove to renew or modify her DEA registration and any pending application for additional registration in Illinois. The denial accompanies the revocation and is included in the Order effective August 6, 2025.
State License Required to Hold DEA Registration
The decision restates that a practitioner must be authorized under the laws of the State in which they practice to dispense controlled substances in order to obtain or maintain a DEA registration. If a practitioner's state license is suspended, revoked, or expired, DEA may revoke the practitioner’s registration.
Failing to Request Hearing Can Lead to Default Revocation
The Order notes that the registrant was served an Order to Show Cause and did not request a hearing, which resulted in a default. Under 21 CFR 1301.43, a default can be deemed a waiver of the right to a hearing and can support a final order revoking registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13825 — Designation of Phenethyl Halides as List I Chemicals
The DEA wants to add phenethyl halides to a special list of chemicals that are closely watched because they can be used to make illegal fentanyl. This means anyone handling these chemicals will have to follow new rules starting soon, no matter how much they have. If you work with these chemicals, get ready to comply and share your thoughts by August 10, 2026!
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Previous / Next Documents
Previous: 2025-12608 — William Washington, M.D.; Decision and Order
Dr. William Washington lost his medical license in Washington state, so the DEA is officially taking away his permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA’s decision is final and immediate. This means Dr. Washington can no longer legally prescribe or manage controlled drugs, effective right now.
Next: 2025-12610 — Mark Agresti, M.D.; Decision and Order
Dr. Mark Agresti from Florida lost his DEA registration because he was convicted of health care fraud and excluded from federal health programs. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can no longer legally prescribe controlled substances, effective immediately, impacting his medical practice and patients.